Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 7/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2543775 | 0.89 | FDPS (0.32) | FDPS | |
| SCHEMBL11301592 | 0.73 | MMP1 (0.35) | FDPS | |
| SCHEMBL11511845 | 0.68 | FDPS (0.52) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL5659978 | 0.65 | FDPS (0.48) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL30823939 | 0.62 | CYP4F2 (0.32) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL9560658 | 0.62 | MEN1 (0.41) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL28117043 | 0.60 | TDP1 (0.35) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL11306475 | 0.60 | FDPS (0.32) | FDPSPDE3A | |
| SCHEMBL450544 | 0.60 | MEN1 (0.32) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL10936504 | 0.59 | FDPS (0.34) | FDPSLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263534-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263534-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | BPGM, SOST, PSPH | FDPS 7/4885PDE3A 2874/4885LMNA 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.